- Home
- CSTL vs GDOT Comparison
CSTL vs GDOT Comparison
Compare CSTL & GDOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSTL
- GDOT
- Stock Information
- Founded
- CSTL 2007
- GDOT 1999
- Country
- CSTL United States
- GDOT United States
- Employees
- CSTL N/A
- GDOT N/A
- Industry
- CSTL Medical Specialities
- GDOT Finance: Consumer Services
- Sector
- CSTL Health Care
- GDOT Finance
- Exchange
- CSTL Nasdaq
- GDOT Nasdaq
- Market Cap
- CSTL 661.7M
- GDOT 742.3M
- IPO Year
- CSTL 2019
- GDOT 2010
- Fundamental
- Price
- CSTL $22.14
- GDOT $12.40
- Analyst Decision
- CSTL Strong Buy
- GDOT Sell
- Analyst Count
- CSTL 6
- GDOT 2
- Target Price
- CSTL $37.67
- GDOT $11.00
- AVG Volume (30 Days)
- CSTL 296.4K
- GDOT 718.3K
- Earning Date
- CSTL 11-03-2025
- GDOT 11-06-2025
- Dividend Yield
- CSTL N/A
- GDOT N/A
- EPS Growth
- CSTL N/A
- GDOT N/A
- EPS
- CSTL N/A
- GDOT N/A
- Revenue
- CSTL $346,269,000.00
- GDOT $1,922,023,000.00
- Revenue This Year
- CSTL N/A
- GDOT $22.03
- Revenue Next Year
- CSTL N/A
- GDOT $12.21
- P/E Ratio
- CSTL N/A
- GDOT N/A
- Revenue Growth
- CSTL 20.40
- GDOT 22.09
- 52 Week Low
- CSTL $14.59
- GDOT $6.13
- 52 Week High
- CSTL $35.84
- GDOT $15.41
- Technical
- Relative Strength Index (RSI)
- CSTL 46.56
- GDOT 41.97
- Support Level
- CSTL $22.16
- GDOT $11.93
- Resistance Level
- CSTL $23.19
- GDOT $12.79
- Average True Range (ATR)
- CSTL 0.89
- GDOT 0.53
- MACD
- CSTL -0.16
- GDOT -0.13
- Stochastic Oscillator
- CSTL 10.05
- GDOT 20.52
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
About GDOT Green Dot Corporation $0.001 par value
Green Dot Corp is a financial technology company that provides financial services for consumers in the United States without good banking options. It has three segments Consumer Services, Business to Business Services(B2B), and Money Movement Services. The company generates maximum revenue from B2B segment. Its B2B Services segment consists of revenues and expenses derived from (i) its partnerships with prominent consumer and technology companies that make banking products and services available to their consumers, partners and workforce through integration with its banking platform (the "Banking-as-a-Service", or "BaaS channel"), and (ii) a comprehensive payroll platform that it offers to corporate enterprises (the "Employer channel") to facilitate payments for today's workforce.